Review of NICE Technology Appraisal Guidance No 55; paclitaxel for the treatment of ovarian cancer

Proposal to move guidance to the static list

As you may be aware the planned date for review of the above guidance was in conjunction with the completion of the ICON5 trial.

Having re-run the search strategy from the original assessment report and considered the findings of the ICON 5 trial, the Institute has not found any relevant additions to the evidence base that would have a material effect on the guidance. Consequently we propose that the original guidance become static.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial. Please see appendix A for a full list of the organisations we have contacted.

Please note all comments received will be published on the Institute’s website when a decision has been taken.